Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
The therapeutic efficacy of troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Hypotonic carboplatin pleurodesis for malignant pleural effusion of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009
Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Elevated circulating activin A levels in malignant pleural mesothelioma patients are related to cancer cachexia and poor response to platinum-based chemotherapy Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema Year: 2020
Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Initial combined intratumoral chemotherapy with cisplatin and irradiation for inoperable non-small cell obstructive lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 492s Year: 2004
Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 436s Year: 2007
Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017